2021-07-04| Asia-Pacific

Australia’s BiomeBank Seeks Approval for the World’s First Microbial Therapy

by Tyler Chen
Share To

Microbiomes have been proven to be linked to several diseases, and scientists worldwide have started to explore the potential of fecal microbiota transplantation (FMT). 

World-First Microbial Therapy

On July 1st, Australia’s BiomeBank submitted its Clostridioides difficile and Ulcerative Colitis treatment to the Therapeutic Goods Administration (TGA) for market authorization. And if the therapy is approved, it would be the first drug for microbial therapy. “We’re positioning BiomeBank as a global leader in microbial drug development with a GMP facility in South Australia, a first-generation microbial therapy now submitted for approval and a rapidly growing portfolio of second-generation products in the pipeline,” said Thomas Mitchell, CEO of BiomeBank. The drug has already been used as an alternative to ulcerative colitis treatment. It is designed to treat patients with recurrent C. difficile and mild to moderate ulcerative colitis by FMT.

BiomeBank Raises $100,000 to Tackle Challenges in FMT Research

Established in 2016, BiomeBank established the first microbial therapy production site in Australia. In mid-2021, it raised $30 million from VC investors to continue research and drug development. The company also has plans to develop microbiome drug products and expand its reach in the Asia Pacific region.

On June 24th,  BiomeBank announced a collaboration with RMIT University in Australia. In addition, it received $100,000 in funding from the Innovative Manufacturing Cooperative Research Centre (IMCRC) to develop bioreactor technology to increase the scale of FMT and decrease the cost. 

Related Article: AbbVie’s JAK1 Inhibitor Aces Ulcerative Colitis Trial, Prospers Amid Tough Regulatory Climate

© All rights reserved. Collaborate with us: [email protected]
Related Post
GeneOnline’s Weekly News Highlights: Nov 20-Nov 24
Deakin University Forms Strategic Partnership with Indian Institute of Technology to Boost Education and Research in India
GeneOnline’s Weekly News Highlights: Oct 30-Nov 3
Topo-1 and FRα: Key Focus Areas and Major Collaborations in ADC Research – Part I
Eli Lilly’s Tirzepatide Gets Approval in China for Weight Loss Management
Roche Reports Positive Clinical Trial Results for Two Diabetes-Related Eye Disease Therapies
7th Person in History Possibly Cured From HIV After Stem Cell Transplant for Acute Myeloid Leukemia
Large RCT Finds Time-Lapse Imaging for Embryo Selection in IVF Does Not Improve Live Birth Rates
Assessment of Supply Chain Risk Key to Improving Medicine Access
SK Biopharma and Full-Life Sign US$571.5 Million Deal for Innovative Radiopharmaceutical FL-091
Scroll to Top